Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis

Don Hayes, Brian S. Murphy, James E. Lynch, David J. Feola

Producción científica: Articlerevisión exhaustiva

39 Citas (Scopus)

Resumen

Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus fumigatus that occur frequently in patients with cystic fibrosis (CF). Recurrent episodes of bronchial obstruction, inflammation, and mucoid impaction occur in ABPA and results in bronchiectasis, fibrosis, and respiratory failure. The treatment of ABPA includes corticosteroids to reduce the acute inflammation and intraconazole to reduce the fungal colonization load in order to reduce lung injury. This case discusses the successful use of aerosolized amphotericin B for the treatment of ABPA in a 14-year-old patient with CF listed for lung transplant. The patient required fewer hospitalizations, and both oral corticosteroids and anti-fungal therapy were eventually stopped. Pediatr Pulmonol. 2010;45:1145-1148.

Idioma originalEnglish
Páginas (desde-hasta)1145-1148
Número de páginas4
PublicaciónPediatric Pulmonology
Volumen45
N.º11
DOI
EstadoPublished - nov 2010

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Huella

Profundice en los temas de investigación de 'Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis'. En conjunto forman una huella única.

Citar esto